Blogs
Dr. Lal PathLabs: It accurately detected single-cell and micrometastases that had been missed during manual reviews. Results were later validated through IHC, confirming the system’s reliability Dr. Lal PathLabs (DLPL) has adopted a deep...
The latest from the Proscia blog Emerging biotechs, along with their small and mid-sized CRO counterparts, are establishing themselves as key players advancing the next generation of therapies. So, in line with our mission to rewire...
The latest from the Proscia blog: Everyone’s talking about AI in therapeutic R&D, but it’s not always easy to cut through the hype to understand where it’s making a real impact today. One of the clearest signals of progress?...
From the Proscia blog: As more laboratories transition from glass slides to images, one sometimes underestimated success factor is laboratory information system (LIS) integration. The LIS continues to underpin the diagnostic workflow, from...
The latest from the Proscia blog. Tom Gallo is Proscia’s Chief Financial Officer. Arun Ananth is the company’s Chief Commercial Officer. For years, AI-driven pathology has promised to deliver top- and bottom-line impact for diagnostic...
Researchers in the University of Tennessee, Knoxville’s Tickle College of Engineering are using artificial intelligence and machine learning to provide treatment plans to breast cancer patients more quickly by analyzing pathology reports...
